Accordingly, previous studies have demonstrated that drugs targeting ESR1, ESR2, and PGR are effective in the treatment of breast cancer and improve promote clinical outcomes (Supplementary Material Tables S1–S3). This evidence concerns the gene ESR1 and breast carcinoma.